Keytruda: Difference between revisions
m Melanie Kusakavtich was also a major contributor to this project. |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Pembrolizumab antibody against programmed cell death-1 receptor== | ==Pembrolizumab antibody against programmed cell death-1 receptor== | ||
<StructureSection load='5dk3' size='350' side='right' caption='Full-Length Crystal Structure of Pembrolizumab (PDB code [[5dk3]])'> | <StructureSection load='5dk3' size='350' side='right' caption='Full-Length Crystal Structure of glycosylated Pembrolizumab complex with sulfate (PDB code [[5dk3]])'> | ||
== Structure and Function == | == Structure and Function == | ||